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Francisella tularensis is a highly virulent facultative intracellular bacterium. The
lack of a safe and efficient vaccine makes antibiotics the preferred treatment.
F. tularensis antibiotic susceptibility tests are based on the in vitro standard CLSI-
approved microdilution method for determining the MIC. However, limited data are
available regarding the minimal inhibitory extracellular concentration (MIEC) needed to
eradicate intracellular bacteria. Here, we evaluated the MIEC values of various WHO-
recommended antibiotics and compared the MIEC values to the established MICs. We
describe a rapid 3-h quantitative PCR (qPCR) intracellular antibiogram assay, which
yields comparable MIEC values to those obtained by the classical 72-h cfu assay. This
rapid qPCR assay is highly advantageous in light of the slow growth rates of F. tularensis.
Our results showed that the MIECs obtained for doxycycline, chloramphenicol and
ciprofloxacin were indicative of intracellular activity. Gentamicin was not effective against
intracellular bacteria for at least 32 h post treatment, raising the question of whether
slow-penetrating gentamicin should be used for certain stages of the disease. We
suggest that the qPCR intracellular antibiogram assay may be used to screen for
potentially active antibiotics against intracellular F. tularensis as well as to detect strains
with acquired resistance to recommended antibiotics.
Keywords: Francisella tularensis, tularemia, antibiogram, intracellular infection, antibiotic susceptibility, qPCR,
MIC, MIEC
INTRODUCTION
Francisella tularensis, the etiological agent of tularemia, is a gram-negative facultative intracellular
bacterium and is one of the most infectious pathogenic bacteria known (Dennis et al., 2001).
As such, it is classiﬁed by the CDC as a category A agent.1 The route of infection and the
bacterial subtype inﬂuence the disease severity. The most severe form of tularemia is caused by
1http://www.bt.cdc.gov/agent/agentlist.asp
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F. tularensis subsp. tularensis (type A), which is found in North
America (Olsufjev and Meshcheryakova, 1983; Staples et al.,
2006), while F. tularensis subsp. holarctica (type B) is responsible
for tularemia across the entire northern hemisphere (Jusatz,
1961). The F. tularensis Live Vaccine Strain (LVS) (Eigelsbach
and Downs, 1961; Tigertt, 1962) is an attenuated type B strain
that does not cause disease in humans but that is virulent to
mice and can infect various cell lines in culture, including human
cell lines (Hall et al., 2007; Krocova et al., 2008). Indeed, many
studies have documented the interaction of F. tularensis with
phagocytic cell lines; however, recent studies have shown that
F. tularensis can attach to and invade non-phagocytic cells such
as lung epithelial cells, endothelial cells, ﬁbroblasts and HepG2
cells (Qin and Mann, 2006; Hall et al., 2007; Moreau and Mann,
2013). Moreover, mice infected with Francisella LVS or SCHU
S4 mutants, which do not eﬃciently replicate in macrophages,
succumbed to infections, suggesting that the interaction of
F. tularensis with non-phagocytic cells plays a role in its virulence
strategy (Horzempa et al., 2010).
Due to the lack of an eﬀective and safe vaccine, antibiotics
are the central strategy for tularemia prophylaxis and treatment.
According to the WHO guidelines (Anda et al., 2007),
gentamicin and streptomycin (as an alternative) are the
recommended antibiotics for treating hospitalized patients with
severe tularemia. These aminoglycosides largely show in vitro
bactericidal activity against F. tularensis types A and B and good
clinical outcomes with minor relapses. The major drawbacks
of aminoglycosides are their associated toxicity and the fact
that they can be administered only parenterally (Enderlin et al.,
1994; Boisset et al., 2014). Fluoroquinolones (ciproﬂoxacin and
levoﬂoxacin) and tetracyclines (doxycycline) are advocated as
ﬁrst-line antibiotics for mild tomoderate tularemia cases (Limaye
and Hooper, 1999; Perez-Castrillon et al., 2001; Ellis et al.,
2002; Tarnvik and Chu, 2007). Ciproﬂoxacin, doxycycline and
chloramphenicol are recommended for less severe cases or
in a mass casualty setting such as post exposure prophylaxis
(Dennis et al., 2001). Recently, it was shown that high-level
ﬂuoroquinolone-resistant mutants could be obtained easily and
quickly (Sutera et al., 2014b). Moreover, some of the resistant
mutants shared cross-resistance to other clinically relevant
antibiotic classes, highlighting the notion that treatment should
not rely only on organism identiﬁcation but rather be based
on the antimicrobial susceptibility testing (AST) results of the
bacteria isolated from the patient. The conditions for performing
AST of F. tularensis are deﬁned by the CLSI guidelines (CLSI,
2010) and are based on the microdilution technique. This process
involves the inoculation of a deﬁned concentration of a bacterial
suspension into a series of dilutions with progressively lower
concentrations of the tested antibiotic. Growth is then monitored
in deﬁned growth medium and conditions. Due to the slow
growth rate of F. tularensis, the AST assay requires 48 h before
the Minimal Inhibitory Concentration (MIC) can be determined.
The MIC is deﬁned as the lowest antibiotic concentration that
completely inhibits bacterial growth, as determined by the un-
aided eye. Knowledge of the MICs allows the assignment of
the bacteria to a susceptibility category (sensitive, intermediate,
resistant or ‘non-sensitive’), which the clinician uses to evaluate
the antibiotic treatment. Notably, however, this AST assay is
conducted in vitro and thus does not address the antibiotic
susceptibility within a living cell. As F. tularensis is a facultative
intracellular bacterium, an antibiotic agent that will be eﬀective
against both the extracellular and intracellular forms is highly
advantageous.
The goal of this study was to develop a rapid and simple
assay to determine the eﬀectiveness of antibiotics against the
intracellular form of F. tularensis, as determined by calculating
the Minimal Inhibitory Extracellular Concentration (MIEC) of
the tested antibiotics. We have developed a rapid 3-h qPCR tool
that provides comparable MIEC values to those obtained by the
classical 72-h cfu assay. Our assay may help to determine the
relationship between the pharmacokinetics (drug concentration
at the site of infection) and the pharmacodynamics (drug
eﬀect on bacterial counts) in the complex environment of the
F. tularensis intracellular infection. The experiments that were
conducted at clinically relevant extracellular drug concentrations
allowed for a comparison of the extracellular and intracellular
activities of relevant antibiotics. Correlation between the MIEC
and MIC values may predict a beneﬁcial clinical outcome
following treatment with the tested antibiotic.
MATERIALS AND METHODS
Bacterial Strains, Media, and Growth
Conditions
Francisella tularensis LVS (ATCC 29684) was grown on CHA
plates (Difco 5.1% cystine heart agar, 1% hemoglobin) for 3 days
at 37◦C. For spinfection experiments, F. tularensis LVSwas grown
in TSBC broth (BD 3% tryptic soy broth, 0.1% L-cysteine) at
37◦C under moderate agitation (150 rpm) to an optical density at
660 nm (OD660) of 0.15–0.3, representing the logarithmic phase.
F. tularensis LVS Growth in Vero Cells
The Vero cell line (ATCC CCL-81) was grown in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) (Biological Industries, Beth
Haemek, Israel) supplemented with 10% fetal calf serum, 2 mM
glutamine and a 1:100 dilution of a non-essential amino-acid
solution (Biological Industries, Beth Haemek, Israel). Cells were
grown at 37◦C in a 5%CO2 humidiﬁed incubator. For spinfection
experiments (Peng et al., 2011; Bradburne et al., 2013), Vero cells
were plated at a concentration of 2 × 105 cells/ml in 24-well
tissue culture plates (1 ml per well) and incubated for 24 h. Cells
were infected with an F. tularensis LVS culture diluted in TSBC
to OD660 = 0.15 (∼5 × 108 cfu/ml) to yield a multiplicity of
infection ratio of 1:3,000. The infected cells were centrifuged for
5 min at 600 g following a 55-min incubation period at 37◦C
in a 5% CO2 humidiﬁed incubator. To remove the extracellular
bacteria, the cell monolayers were washed three times with
sterile phosphate-buﬀered saline (PBS, Biological Industries, Beth
Haemek, Israel) and then treated for 1 h at 37◦C with 20 μg/ml
gentamicin (Sigma G1397), followed by three washes with sterile
PBS. The infection yield was determined by harvesting the cell
fraction with 1 ml of 0.1% sodium deoxycholate (Sigma D6750)
per well for 1 min, and cfu counts were determined by plating
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10-fold dilutions on CHA plates. All experiments were run in
duplicate, and the averages of the duplicate results are presented
in the ﬁgures.
MIC and MBC Determination
Antibiotic susceptibility tests were performed by the standard
microdilution method, according to the CLSI guidelines for
F. tularensis (CLSI, 2010). F. tularensis LVS was prepared
by being plated on CHA plates and incubated for 3 days
at 37◦C in ambient air. Isolated colonies were suspended to
OD660 = 0.075 (∼1–4 × 108 cfu/ml) in cation-adjusted Mueller-
Hinton broth (BBL, 212322) supplemented with 2% deﬁned
growth supplement (IsoVitaleX Enrichment; BBL 211876) and
3 μM hematin (Sigma 3281). The bacterial suspension was
diluted 1:100 and inoculated in duplicate into 96-well microtiter
plates containing twofold serial dilutions of each antimicrobial
agent to yield approximately 5 × 105 to 2 × 106 cfu/ml
in a ﬁnal volume of 100 μl. The inoculum size was veriﬁed
by plating 10-fold dilutions on CHA and incubating 3 days
at 37◦C for cfu counts. The microtiter plates were incubated
in a plate reader (TECAN Sunrise or Inﬁnite 200) for 48 h
at 37◦C in ambient air, and the absorbance at OD630 was
read at 1-h intervals. The following antibiotics were used:
doxycycline (Sigma D9891), ciproﬂoxacin (Ciproxin 200, Bayer),
erythromycin (Sigma E5389), chloramphenicol (Sigma C0378)
and gentamicin (Sigma G1397). The MICs of ciproﬂoxacin and
doxycycline were determined by >10 independent repetitions,
and those of gentamicin, chloramphenicol and erythromycin
by four independent repetitions. The MIC was deﬁned as the
lowest concentration that reduced growth to less than 10% of the
OD630 of the growth control, and the lack of visible growth was
veriﬁed by the unaided eye. The Quality Control (QC) strains
Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC
25922 were used to ensure consistent MIC results within the
deﬁned reference MIC range (CLSI, 2015).
The minimal bactericidal concentration (MBC) were
determined following the CLSI guidelines (CLSI, 1999). The
MBC was determined by plating the content of the microtiter
plate wells containing MIC and higher concentrations of
antibiotics on CHA plates and incubating at 37◦C for 5 days for
viable cfu counts. The MBCwas determined as the concentration
that caused a 3-log decrease in cfu counts compared with the
original inoculum. MBCs were determined in at least three
independent repetitions.
MIEC Determination
For intracellular antibiogram assays, spinfected cells were grown
for 24 h in fresh supplemented DMEM containing 20 μg/ml
gentamicin (Sigma G1397) and a twofold dilution series of the
tested antibiotic. Post incubation, the medium from eachwell was
collected to determine the cfu counts, and the cell monolayers
were washed three times with sterile PBS, harvested by adding
1 ml of 0.1% sodium deoxycholate (Sigma D6750) to each well for
1 min and collected for both quantitative PCR (qPCR) analysis
and bacterial cfu counts. The cell fraction and the medium were
serially diluted and plated on CHA plates for cfu counts. The
MIEC was determined as the minimal antibiotic concentration
that prevents bacterial growth in the cellular fraction.
Quantitative PCR Analysis
For qPCR analysis, a sample of 100 μl cell extract was ﬁrst added
to 100 μl Triton buﬀer (20% Triton X-100 (Sigma T8787) in
TE buﬀer) and heated for 30 min at 100◦C. DNA was then
puriﬁed with the QIAamp DNA blood mini kit (QIAGEN
51104) and subjected to real-time PCR using the SensiFASTTM
Probe Lo-Rox kit (Bioline BIO-84005) with an Applied
Biosystems 7500 real-time PCR system. DNA quantiﬁcation
was performed based on the gene fopA, as previously described
(Versage et al., 2003). The primers (fopAF: ATCTAGCAGGTCA
AGCAACAGGT, fopAR: GTCAACACTTGCTTGAACATTT
CTAGATA) and the dual-labeled probe (fopAP: 6-FAM-
CAAACTTAAGACCACCACCCACATCCCAA-BHQ-1) were
ordered from Integrated DNA Technologies, Inc.
To determine the cfu/ml equivalents of the qPCR assay, 10-
fold dilutions of F. tularensis LVS cultures, pre-quantiﬁed by the
cfu counts, were used as a reference. Equivalent cfu/ml were
determined from the standard curve using 7500 Real-Time PCR
System Sequence Detection Software (v1.4, Applied Biosystems,
Inc.).
Immunolocalization of F. tularensis LVS
in Cultured Vero Cells by Confocal
Microscopy
Quantiﬁcation of intra/extracellular bacteria using double-
labeled immunoﬂuorescence has been previously described (Law
et al., 2014). Brieﬂy, Vero cells were seeded on #1 glass cover
slips in 24-well dishes and spinfected with F. tularensis. Cells
were ﬁxed with 4% paraformaldehyde (PFA, Gadot, Israel) for
10 min at 4◦C, washed three times with PBS, and placed for 1 h
in a blocking solution [10% normal goat serum (NGS) in PBS
containing 0.05% Tween-20 (Sigma–Aldrich P5927)].
Staining of Extracellular Bacteria
The cells were incubated in a 1:500 dilution of primary rabbit
anti-F. tularensis hyper-immune serum in an antibody cocktail
solution (50% blocking solution/0.05% Tween-20/PBSX1) for
24 h at 4◦C. Then, the slides were washed three times
(5 min each) with washing buﬀer (1% blocking solution/0.05%
Tween-20/PBSX1), incubated with secondary Alexa Fluor-488
(Molecular Probes, Life Technologies, Burlington, ON, Canada)
at a 1:250 dilution in an antibody cocktail solution for 24 h at 4◦C,
and washed three times with washing buﬀer.
Staining of Intracellular Bacteria
Cell membranes were permeabilized [0.2% Triton X-100 (TX-
100)/PBSX1] for 10 min, blocked again for 1 h [10% NGS in
PBS containing 0.05% TX-100], incubated in a 1:500 dilution
of primary rabbit anti-F. tularensis hyper-immune serum in
antibody cocktail solution (50% blocking solution/0.05% TX-
100/PBSX1) for 24 h at 4◦C. Then, the membranes were washed
three times (5 min each) with washing buﬀer (1% blocking
solution/0.05% TX-100/PBS), and incubated with a mixture of
secondary Alexa Fluor-594 (1:250 dilution) (Molecular Probes,
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Life Technologies, Burlington, ON, Canada) in an antibody
cocktail solution for another 24 h at 4◦C. In the last step, nuclei
were stained with DAPI (1 μg/ml, Sigma D9542) for 5 min at
room temperature. Following three additional washes, the cells
were mounted on slides using Fluoromount G (Southern Biotech,
Birmingham, AL, USA). Images were acquired using a Zeiss
LSM710 confocal microscope (Zeiss, Oberkochen, Germany).
From each slide, ﬁve random ﬁelds were scanned for ﬂuorescence
quantiﬁcation. Analysis was conducted using Zen1 (Zeiss,
Oberkochen, Germany). Fluorescence intensity parameters were
statistically analyzed using a t-test followed by the Mann–
Whitney U test. Uninfected cells and infected cells processed in
the absence of anti F. tularensis hyper-immune serum served as
negative controls.
RESULTS
Invasion and Intracellular Growth of
F. tularensis LVS in Vero Cells
The entry of F. tularensis LVS into epithelial cells is believed to be
less eﬃcient than the uptake into macrophages (Hall et al., 2007;
Bradburne et al., 2013); thus, we ﬁrst optimized the infection
procedure of F. tularensis LVS into Vero cells. We based our
initial experiments on previous work describing the spinfection
technique in Vero cells using centrifugation conditions of 600 g
for 15 min at room temperature (Keren et al., 1995; Keysary
et al., 1996). Using these conditions, followed by 45 min of
incubation at 37◦C in a 5% CO2 humidiﬁed incubator for a
total infection period of 60 min, we found that a multiplicity of
infection (MOI) of 1:3,000 yielded the maximal cell-associated
bacteria from all tested MOIs (Figure 1A). We then worked to
optimize the centrifugation time. Vero cells were spinfected with
F. tularensis LVS at an MOI of 1:3,000 without centrifugation
or with various centrifugation times (5, 15, 30, and 60 min).
Following centrifugation, cells were incubated at 37◦C in a 5%
CO2 humidiﬁed incubator for a total infection period of 60 min.
We found that both 5 and 15 min of centrifugation yielded
the highest F. tularensis LVS cfu counts associated with the cell
fraction. Cfu counts of 100s to several 1000s were consistently
recovered from each well (Figure 1B). Following these results, all
the experiments described in this work were performed using an
MOI of 1:3,000 and 5 min of centrifugation following 55 min of
incubation at 37◦C in a 5% CO2 humidiﬁed incubator.
To remove the remaining free extracellular bacteria,
supplemented DMEM medium containing 20 μg/ml gentamicin
was added to the cell culture for 1 h. This resulted in a 4–5-
log decrease of the cfu counts in the medium (Figure 1C).
Surprisingly, although gentamicin does not accumulate in cells
within an hour (Carryn et al., 2003), we also observed a 2–3-log
decrease in viable bacteria counts in the cell fraction (Figure 1D),
suggesting that most of the cell-associated bacteria (∼98%) were
not located within the cells but were adhered to the cell surface,
where they are partially exposed to the bactericidal eﬀect of
gentamicin. We then checked the cfu counts in the medium and
found a continuous rise following infection (Figure 1E) and up
to 48 h (data not shown). Of note, our supplemented DMEM
control without Vero cells, supported growth of approximately
1 log/24 h of F. tularensis LVS (data not shown). This minor
growth, which was not observed by others (Maurin et al., 2000;
Ludo et al., 2008), cannot account for the majority of the bacteria
that we found in the medium, suggesting a continuous release
of the adhered bacteria to the external medium. The presence
of bacteria in the medium indicated a need for the continuous
presence of gentamicin in the MIEC determination assay to
prevent extracellular growth and the possible reinoculation of
cells by these bacteria.
To verify that F. tularensis LVS indeed invaded Vero cells
and was not merely associated with the cell fraction, we used
confocal microscopy to ascertain the bacterial localization
within the cell fraction. Using diﬀerential staining conditions,
we could discriminate the outer membrane-associated
bacteria (Figure 2AI) from the intracellular F. tularensis
LVS (Figure 2AII), and we thus conﬁrmed the presence of the
bacteria within the Vero cells (Figure 2AIV). No ﬂorescence
intensity was observed in non-infected cells and in the absence
of anti-F. tularensis serum (data not shown).
The low invasion rates of F. tularensis LVS in Vero cells
compared with those reported for macrophage cell lines (Hall
et al., 2007) may raise the question of whether F. tularensis is
capable of replicating in Vero cells. To clarify this question we
measured the ﬂuorescence intensity of both intracellular and
outer membrane-associated bacteria. Nuclei stained with DAPI
are presented in Figures 2AIII,VII,XI and merged images of
DAPI, outer membrane and intracellular bacteria labeling are
demonstrated in Figures 2AIV,VIII,XII. We found that at 5
and 24 h post infection there was a signiﬁcant increase in
the ﬂuorescence intensity of intracellular bacteria over time, as
shown in Figures 2AII,VI,X. The bacteria were observed within
the cytosolic compartment surrounding the nucleus (Figure 2B).
The ﬂuorescence intensity of the outer membrane-associated
bacteria was similar immediately and 5 h post infection but
decreased by threefold at 24 h post infection (Figures 2AI,V,IX).
We postulate that the ﬂuorescence of the outer membrane-
associated bacteria represents bacteria that are embedded in the
Vero cell membranes as the result of the centrifugation process.
The ratio of intracellular ﬂuorescence to outer membrane
ﬂuorescence increased dramatically within 24 h (Figure 2C),
suggesting that the invading bacteria indeed replicated within the
Vero cells.
To quantify the growth of the intracellular bacteria, we
monitored the intracellular growth rates of the bacteria following
infection. To verify that the scored bacteria were intracellular,
cultures were grown in parallel with and without the addition
of 20 μg/ml gentamicin to the cell growth medium. We found
that despite the low invasion rates, F. tularensis LVS was
capable of replicating in Vero cells, as shown in Figure 2D.
The bacterial load increased by ∼1,000-fold in 24 h, reaching
the late exponential phase. A similar rate of growth was
documented by others in optimized modiﬁed Mueller-Hinton
broth, in macrophages, HEp-2 cells, human bronchial epithelial
cells and A549 tissue culture cells (Lindemann et al., 2007).
The addition of gentamicin did not impair the growth of
intracellular bacteria for at least 32 h, suggesting that the
Frontiers in Microbiology | www.frontiersin.org 4 November 2015 | Volume 6 | Article 1213
Aloni-Grinstein et al. MIEC determination of F. tularensis
FIGURE 1 | Optimization of the infection procedure of Vero cells by Francisella tularensis LVS. Vero cells were spinfected with F. tularensis LVS with a
multiplicity of infection (MOI) ratio of 1, 10, 100, or 3,000. Bacteria within the cell fraction were extracted and quantitated using cfu counting (A). The optimal
centrifugation time was determined using an MOI of 1:3,000 by comparing the yields obtained without centrifugation to those obtained with various centrifugation
times (5, 15, 30, and 60 min) (B). The effect of a 1-h 20 μg/ml gentamicin treatment on the extracellular fraction (C). The effect of a 1-h 20 μg/ml gentamicin
treatment on the cellular fraction. (D) Concentrations of bacteria released from the cell fraction following infection and a 1-h gentamicin treatment (E).
observed increase in bacterial counts was of an intracellular
origin. These results are in agreement with previously published
data demonstrating that the activity of aminoglycosides against
intracellular F. tularensis increases progressively with time and
reaches signiﬁcant intracellular levels only after 48 h (Tulkens and
Trouet, 1978; Maurin and Raoult, 1993).
The Determination of MIEC Values in
Epithelial Vero Cells
The exposure to diﬀerent antibiotic concentrations was initiated
1 h after the infection of Vero cells with F. tularensis LVS, and the
MIECs were determined 24 h following the initiation of antibiotic
treatment, during the late logarithmic phase (Figure 2D), both
by the cfu method following 3 days of incubation (Figure 3)
and by the 3-h qPCR method (Figure 4). The antibiotic agents
ciproﬂoxacin, doxycycline and chloramphenicol were selected
because they are recommended for treatment in a contained
casualty setting (Dennis et al., 2001), although the use of
chloramphenicol is limited to exceptional cases due to the serious
side eﬀects associated with the drug (Kreizinger et al., 2013).
F. tularensis LVS was shown to be resistant to azithromycin
(Ahmad et al., 2010) and to erythromycin (Biswas et al., 2008).
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FIGURE 2 | Assessment of the intracellular and outer membrane-associated F. tularensis bacteria. Vero cells infected with F. tularensis LVS bacteria were
analyzed using a confocal microscope. All cell cultures were treated for 1 h with 20 μg/ml gentamicin following 3xPBS washes. Cell cultures of 5 and 24 h were
grown in medium containing 20 μg/ml gentamicin. Double-labeled immunofluorescent images of F. tularensis LVS infections of Vero cells after 0, 5, and 24 h are
presented in (A). Bacteria bound to the outer membrane appear green (AI,V,IX) or yellow in merged panels (AIV,VIII,XII), while intracellular bacteria appear
exclusively red (AII,VI,X). Nuclei stained with DAPI are presented in images (AIII,VII,XI). The frame size in (AI–XII) is 512 × 512, the dimensions are
70.71 × 70.71 μm, the magnification is x120, and the scale bar = 20 μm. A representative optical slice of the 3D analysis of a nucleus surrounded by bacteria in
infected cells is presented in (B). The images represent fluorescent (BI) and surface projections (BII) of the same cell 5 h post infection. Frame size: 512 × 512;
dimensions: 73.15 × 73.15 × 23 μm; magnification: x120; scale bar = 20 μm. The ratio between the fluorescent intensity of intracellular versus outer
membrane-associated bacteria labeling is presented in (C). All experiments were performed in duplicate and repeated three times. Bacterial growth curves in the
cellular fraction of Vero cells were monitored by cfu counts in the presence (red line) or absence of gentamicin (blue line). The experiment was performed in
duplicate (D).
Resistance to erythromycin was shown to correlate with a
point mutation in domain V of the 23S rRNA, which could
explain the heterogeneity in susceptibility to erythromycin for
F. tularensis strains (Biswas et al., 2008). Erythromycin was
chosen to show the validity of the qPCR assay in an extreme
case of resistance to a tested antibiotic. The MIECs determined
by the cfu method (Figure 3) and qPCR method (Figure 4) were
within one dilution of each other, despite the diﬀerent readouts
obtained by the two methods. The diﬀerences can be attributed
to the methods of measurement. While the cfu counts assay
measures only viable bacteria, the qPCR technique measures also
non-culturable forms or killed bacteria that are in the process
of DNA degradation. MIEC values were presented as a range
when diﬀerent values were obtained in repetitions (Table 1).
The MIECs of ciproﬂoxacin, doxycycline and gentamicin were
determined by ﬁve repetitions, of chloramphenicol by two
repetitions and of erythromycin by one repetition.
Standard MIC and MBC Determination
The MIC value was deﬁned as the lowest concentration that
reduced growth to less than 10% of the OD630 of the no-antibiotic
growth control (equivalent to no visible growth by the aided
eye). MIC values are presented in Table 1 as a range to include
all the values obtained in repetitions. F. tularensis LVS displayed
the expected ‘susceptible’ category, as determined by MICs of
0.008–0.016 μg/ml, which is ≤0.5 μg/ml for ciproﬂoxacin,
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FIGURE 3 | The intracellular activities of antibiotics, as determined by cfu counting. Vero cells were spinfected (MOI 1:3,000) with F. tularensis LVS, treated
for 1 h with 20 μg/ml gentamicin, following 3xPBS washes. Fresh supplemented DMEM containing 20 μg/ml gentamicin and the tested antibiotic at a twofold
dilution was added. The plates were incubated at 37◦C in 5% CO2 atmosphere. After 24 h, the cell fractions were harvested and serially diluted by 10-fold in PBS
following plating on CHA plates and were incubated for 72 h for cfu counts. MIECs were defined as no growth based on the initial infected concentration.
Ciprofloxacin (A), doxycycline (B), chloramphenicol (C) and erythromycin (D). All experiment were performed in duplicate. The number of repetitions for each
antibiotic is stated in Table 1. The graphs are representatives of the repetitions.
0.06–0.25 μg/ml, which is ≤4 μg/ml for doxycycline,
0.03–0.06 μg/ml, which is ≤4 μg/ml for gentamicin, and
0.5–1 μg/ml, which is ≤8 μg/ml for chloramphenicol.
As expected (Keim et al., 2007; Biswas et al., 2008), the
F. tularensis LVS showed a high MIC value (>256 μg/ml)
to erythromycin (Table 1), indicating the resistance of LVS.
Notably, however, there are no susceptibility categories of
macrolides for F. tularensis, as it is not a recommended
compound for clinical treatment. The MBC values, which
represent the survival of the bacteria during the 48 h of
the AST in growth inhibitory concentrations (i.e., the MIC
and higher concentrations), were determined as 99.9%
reduction in cfu counts compared with the initial inocula.
An MBC/MIC ratio <8 was considered bactericidal, and a
ratio ≥8 was considered as a bacteriostatic mode of action
(Pankey and Sabath, 2004). As expected, doxycycline showed
a bacteriostatic mode of action, as noted by an MBC value
of 32 μg/ml, and an MBC/MIC ratio of ≥64. The expected
bactericidal mode of action is indicated for ciproﬂoxacin,
as MBC values were in the range of 0.032–0.064 μg/ml and
an MBC/MIC of ≤4. Gentamicin also demonstrated the
expected bactericidal mode of action, with an MBC/MIC
ratio of 1–2. Chloramphenicol, which is known to exhibit
both bacteriostatic and bactericidal actions, depending on the
bacteria, showed a clear bactericidal mode of action against
F. tularensis LVS, with an MBC of 4 μg/ml and an MBC/MIC
ratio of 4. Thus, as far as the in vitro activity indicates, all
four recommended antibiotics are expected to be eﬃcacious
against the extracellular form of the bacteria under conventional
treatment.
DISCUSSION
Tularemia is considered a re-emerging disease. In the last decade,
sporadic cases and outbreaks in various locations in the U.S.
and Europe have been documented (CDC, 2013; Johansson
et al., 2014; Mailles and Vaillant, 2014). Moreover, F. tularensis
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FIGURE 4 | The intracellular activities of antibiotics, as determined by qPCR. Vero cells were spinfected (MOI 1:3,000) with F. tularensis LVS, treated for 1 h
with 20 μg/ml gentamicin following 3 PBS washes. Fresh supplemented DMEM containing 20 μg/ml gentamicin and the tested antibiotic at a twofold dilution was
added. After 24 h, the cell fractions were harvested, and a sample of 100 μl cell extract was added to 100 μl Triton buffer and heated for 30 min at 100◦C. DNA was
then purified and subjected to qPCR to determine PCR-equivalent cfu values. MIECs were defined as no growth based on the initial infected concentration.
Ciprofloxacin (A), doxycycline (B), chloramphenicol (C), and erythromycin (D). All experiment were performed in duplicate. The numbers of repetitions for each
antibiotic is stated in Table 1. The graphs are representatives of the repetitions.
is deﬁned as a category A potential bioterrorism agent by the
CDC.2 The lack of an eﬀective vaccine places antibiotics as
the only treatment option. In addition to naturally occurring
antibiotic resistance such as the resistance of F. tularensis
subsp. holarctica biovar II to erythromycin in contrast to the
erythromycin-susceptible biovar I (Keim et al., 2007), in vitro
selected resistance (Gestin et al., 2010; Sutera et al., 2014b)
may also be of concern if misused for bioterrorism. To develop
new or alternative antibiotic treatments, determining whether
both the extracellular and intracellular forms of the bacteria
are sensitive to the tested antibiotic is important. Moreover,
due to diﬀerent sub-cellular pharmacokinetics and variables
such as speciﬁc inﬂux/eﬄux ratios, binding, tissue metabolism,
and the accumulation and bioavailability of an active antibiotic
form, no simple correlation can predict a connection between
the cellular concentration of antibiotics and the bacterial
responsiveness (Van-Bambeke et al., 2006). Compared to the
MIC AST, the MIEC test adds another level of prediction, as
2http://www.bt.cdc.gov/agent/agentlist.asp
the assay reﬂects the dynamic eﬀects of drugs on the host cell-
intracellular microorganism relationship. Unlike animal models,
which cannot be standardized or compete with the in vitro
assay time scales, the cell line model has the advantage of both
the ‘static’ antibiotic concentration of the in vitro microdilution
method, and some aspects of the in vivo host-pathogen
interaction. These include diﬀerences in pharmacokinetics at
various internal compartments and pharmacodynamic properties
such as local microenvironment pH diﬀerences, binding of the
antibiotics to internal structures/proteins and interaction with
speciﬁc degrading/modifying enzymes. Yet, the cell line model
has its drawbacks and cannot replace the ﬁnal in vivo challenge in
the animal model, as factors like Cmax , serum elimination half-
life rates, serum protein binding, involvement of the immune
system and other host defense mechanisms, cannot be evaluated.
Nevertheless, screening for new antibiotic compounds against
intracellular bacteria in the MIEC assay may be used to predict
antimicrobial eﬃciency, making the MIEC assay a relevant
approach that can reduce the use of animals for testing non-
relevant compounds.
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TABLE 1 | The activities of antibiotics against Francisella tularensis Live
Vaccine Strain (LVS), as determined in vitro by the broth microdilution
method (MIC) vs. the intracellular activity determined by cfu and qPCR
(MIEC).
Antibiotic agent ∗MIC (µg/ml) ∗∗MIEC (µg/ml)
by CFU by qPCR
Ciprofloxacin 0.008–0.016 0.06–0.25 0.06–0.25
Doxycycline 0.06–0.25 0.125–0.5 0.125–0.5
Chloramphenicol 0.5–1 1.0–2.0 1.0–2.0
Gentamicin 0.03–0.06 >20 >20
Erythromycin >256 >256 >256
∗MIC-minimal inhibitory concentration. ∗∗MIEC-minimal inhibitory extracellular
concentration. MICs were determined for ciprofloxacin and doxycycline by
10 repetitions and for gentamicin, chloramphenicol and erythromycin by four
repetitions. MIECs were determined for ciprofloxacin, doxycycline and gentamicin
by five repetitions, for chloramphenicol by two repetitions and for erythromycin by
one repetition. All experiments were performed in duplicate.
Usually, the intracellular activity of a tested antibiotic against
intracellular facultative microorganisms such as F. tularensis
is measured by the viable bacterial counts, as determined
by measuring the cfu. Because F. tularensis is a slow-
growing bacterium, this assay is time consuming, and as
many as 3 days may be needed to obtain 1–2 mm colonies.
Thus, we have adapted a qPCR assay that quantiﬁes the
inhibition of bacterial growth within 3 h. We compared
the MIECs obtained by the qPCR and cfu assays and
examined four of the ﬁrst-line recommended antibiotics for the
treatment of tularemia (ciproﬂoxacin, doxycycline, gentamicin
and chloramphenicol). We chose these antibiotics since they
have standard test conditions and susceptibility categories
for F. tularensis by the clinical and laboratory standard
institute (CLSI, 2010). Furthermore, they represent diﬀerent
modes of action, usually aminoglycosides and ﬂuoroquinolones
being bactericidal (concentration dependent mode of killing),
tetracyclines considered bacteriostatic (exposure time-dependent
killing) and the nature of chloramphenicol mode of action
is dependent on the bacteria (bactericidal for F. tularensis).
In addition, we chose erythromycin, which is eﬀective against
several subtypes of F. tularensis but not against F. tularensis
LVS, to show the validity of the qPCR-MIEC assay also with
resistant strains. Our results show that the MIECs obtained by
cfu counts were the same as those obtained by qPCR, suggesting
that during the evaluation of a virulent strain, qPCR may serve
as a quicker alternative for determining the MIECs. Moreover,
the MIECs obtained for doxycycline and chloramphenicol were
similar to the in vitroMIC values, indicating that both antibiotics
were eﬀective against the intracellular as well as the extracellular
bacteria at the time point tested. These results are in agreement
with the fact that the accumulation level at equilibrium, that is,
the ratio between the cellular concentration and the extracellular
concentration, of tetracyclines in cultured macrophages is 1–4
and that the time from inﬂux to equilibrium is only minutes
(Carryn et al., 2003; Van-Bambeke et al., 2006). However, the
MIECs of ciproﬂoxacin were 8- to 16-fold higher than the MICs,
suggesting that the intracellular bacteria experienced some degree
of protection. Whether the internal ciproﬂoxacin concentration,
which was shown to be 4–7 times the extracellular concentration
in neutrophils is fully active is not clear (Easmon and Crane,
1985). This antibiotic may be subjected to strong eﬄux activity
from the phagosomes in which intracellular F. tularensis resides
or may be partly inactive, as ciproﬂoxacin has only 1/15 of the
activity against internal bacteria as it does against extracellular
bacteria, despite similar internal concentrations in macrophages
(Carryn et al., 2002). The MIEC values for erythromycin and
gentamicin were high. The high erythromycin MIEC correlated
with the high MIC due to the intrinsic resistance of this strain of
F. tularensis to erythromycin. However, the MIC for gentamicin
was low (0.03–0.06 μg/ml), and the MIECwas high (>20μg/ml),
suggesting that F. tularensis LVS is sensitive to gentamicin but
that the intracellular concentration of gentamicin 24 h post
treatment is not suﬃcient to achieve growth arrest (Figure 2D).
Indeed, the time needed for gentamicin to reach equilibrium
in several cell types is several days (Van-Bambeke et al., 2006).
Our results show that only after 2 days of gentamicin treatment,
an eﬀect on the growth of intracellular bacteria was observed.
Others report that gentamicin given 24 h post infection to
SCHU S4-infected mice is expected to start accumulating in
phagocytic vesicles only several days after treatment initiation,
and the eﬀect observed in the infected mice is likely due to the
suppression of replication of the extracellular bacteria, leading
to decreased dissemination of bacteria from the lungs to distal
organs (Sutherland et al., 2012). Notably, the retrospective report
on treatment failure in tularemia patients who did not receive
prompt treatment (Kaya et al., 2012) showed that treatment
failed in 4 out of 7 patients treated with gentamicin but in only
one patient out of 13 receiving streptomycin and in one patient
out of seven receiving ciproﬂoxacin, emphasizing the diﬀerences
in responsiveness to gentamicin during diﬀerent phases of the
disease.
Recently, a new dye uptake assay that tests the activity of
antibiotics against intracellular F. tularensiswas described (Sutera
et al., 2014a). This assay takes advantage of the cytotoxic eﬀect of
bacteria on eukaryotic cells. The activity of the tested antibiotic is
scored by its potential to prevent cytotoxic eﬀects by inhibiting
bacterial activity. Because this assay does not directly measure
the eﬀect of the tested antibiotic on the bacteria but instead
assesses a secondary eﬀect, the assay is time consuming, taking
5 days. Notably, the direct cfu assay is also on the scale of 3 days.
In contrast, our qPCR assay directly measures the eﬀect of the
antibiotic on the bacteria, and the results are obtained within
1 day following the initiation of treatment. Thus, the qPCR assay
is superior to the dye uptake and cfu assays in terms of time
eﬃciency.
Although the study by Sutera et al. (2014a) and ours examined
diﬀerent strains of F. tularensis subsp. holarctica, the MICs
for ciproﬂoxacin, doxycycline and gentamicin were comparable.
However, while the MIECs for ciproﬂoxacin and doxycycline
were also comparable, the values for gentamicin were very
diﬀerent. Whereas the MIEC was above 20 μg/ml in our study,
the Sutera et al. (2014a) study found an MIEC of 2 μg/ml. These
diﬀerences may be attributed to the diﬀerent durations of the
diﬀerent assays. In the qPCR assay, the bacteria are scored for
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MIEC determination within 24 h of the initiation of treatment.
During this period, gentamicin does not usually penetrate the
cells; thus, high MIECs are expected. However, gentamicin does
penetrate the cells during the 5-day incubation period of the
dye uptake assay. Indeed, the MIECs were lower (2 μg/ml)
than those we observed but were somewhat higher than
the MIC values, indicating that gentamicin is less eﬀective
against intracellular F. tularensis, as previously suggested by the
authors (Sutera et al., 2014a). The discrepancy in the MIEC
values obtained by the diﬀerent assays may be of clinical
relevance both in the evaluation of new antibiotics and in
determining eﬀective treatment options for diﬀerent stages of
the disease. In cases in which an immediate eﬀective response
against the intracellular bacteria is required, gentamicin or
other slow-penetrating antibiotics may not be the preferred
choice.
CONCLUSION
We showed that F. tularensis LVS bacteria are capable of
invading and replicating in epithelial Vero cells. The exponential
phase lasted for 24 h and allowed a 1,000-fold increase in
the initial load. The bacteria were observed in the cytosolic
compartment surrounding the nucleus. Indeed, F. tularensis
was shown by others to develop mechanisms of adaptation to
cytosolic proliferation (Celli and Zahrt, 2013). We used this
model to study the eﬀectiveness of various ﬁrst-line antibiotics
against the intracellular bacteria and found that the qPCR assay
provided accurate MIEC values compared to those obtained
by cfu counts. Furthermore, the qPCR assay is quicker than
the cfu assay. This approach is of great value in light of the
slow growth rates of F. tularensis. Thus, the qPCR intracellular
antibiogram assay may facilitate the future standardization of
intracellular antibiogram processes and may help to evaluate the
eﬀectiveness of new compounds against the intracellular form
of F. tularensis. Moreover, high MIEC values indicate a low
intracellular activity/concentration and may explain treatment
failure.
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